Cargando…

V-Domain Ig Suppressor of T Cell Activation (VISTA) Expression Is an Independent Prognostic Factor in Multiple Myeloma

SIMPLE SUMMARY: Multiple myeloma (MM) is characterized by loss of anti-tumor T-cell immunity. The precise mechanisms by which malignant plasma cells escape T-cell immunity are unknown, although upregulation of checkpoint molecules is seen in progressive disease. The aim of our study was to investiga...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mutsaers, Pim, Balcioglu, Hayri E., Kuiper, Rowan, Hammerl, Dora, Wijers, Rebecca, van Duin, Mark, van der Holt, Bronno, Broijl, Annemiek, Gregory, Walter, Zweegman, Sonja, Sonneveld, Pieter, Debets, Reno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124446/ https://www.ncbi.nlm.nih.gov/pubmed/34066382 http://dx.doi.org/10.3390/cancers13092219

Ejemplares similares

Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
por: Hofste op Bruinink, Davine, et al.
Publicado: (2022)

Pomalidomide in Patients With Relapsed and/or Refractory Multiple Myeloma: A Prospective Study Within the Nationwide Netherlands Cancer Registry
por: Wester, Ruth, et al.
Publicado: (2022)

Carfilzomib Combined With Thalidomide and Low-dose Dexamethasone for Remission Induction and Consolidation in Newly Diagnosed Transplant Eligible Patients With Multiple Myeloma: 8 vs 4 Induction Cycles; the Carthadex Trial
por: Wester, Ruth, et al.
Publicado: (2020)

Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
por: Wester, Ruth, et al.
Publicado: (2019)

Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer
por: Hammerl, Dora, et al.
Publicado: (2021)

Intratumoral Niches of B Cells and Follicular Helper T Cells, and the Absence of Regulatory T Cells, Associate with Longer Survival in Early-Stage Oral Tongue Cancer Patients
por: Phanthunane, Chumut, et al.
Publicado: (2022)

VS38c and CD38-Multiepitope Antibodies Provide Highly Comparable Minimal Residual Disease Data in Patients With Multiple Myeloma
por: Broijl, Annemiek, et al.
Publicado: (2021)

Treatment emergent peripheral neuropathy in the CASSIOPEIA trial
por: Fokkema, Cathelijne, et al.
Publicado: (2022)

Lack of B and T cell reactivity towards IDH1(R132H) in blood and tumor tissue from LGG patients
por: Weenink, Bas, et al.
Publicado: (2019)

B07 HIGH EXPRESSION OF NUCLEAR CEREBLON IS ASSOCIATED WITH LONGER SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH IMIDS
por: Wester, R., et al.
Publicado: (2023)

Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects
por: Ubels, Joske, et al.
Publicado: (2018)

OAB-029: Single-cell transcriptomic analysis reveals reduction of cytotoxic NK cells in a subset of newly diagnosed multiple myeloma patients impacting outcome after daratumumab therapy
por: Tahri, Sabrin, et al.
Publicado: (2022)

Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
por: Brink, Mirian, et al.
Publicado: (2021)

B05 PLASMA CELL LEUKEMIA-LIKE STATUS HAS INDEPENDENT PROGNOSTIC VALUE IN THE CONTEXT OF THE SECOND REVISION OF THE INTERNATIONAL STAGING SYSTEM
por: Hofste op Bruinink, D., et al.
Publicado: (2023)

A gene expression based predictor for high risk myeloma treated with intensive therapy and autologous stem cell rescue
por: Wu, Ping, et al.
Publicado: (2015)

Gene Expression Profile Alone Is Inadequate In Predicting Complete Response In Multiple Myeloma
por: Amin, Samirkumar B., et al.
Publicado: (2014)

P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: D’agostino, Mattia, et al.
Publicado: (2023)

B01: STROMAL CELL-NEUTROPHIL INTERACTIONS PROMOTE A PRO-TUMOR ENVIRONMENT IN MULTIPLE MYELOMA
por: de Jong, M, et al.
Publicado: (2022)

Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma
por: Sonneveld, Pieter, et al.
Publicado: (2022)

Efficacy and safety of daratumumab combined with all-trans retinoic acid in relapsed/refractory multiple myeloma
por: Frerichs, Kristine A., et al.
Publicado: (2021)

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands
por: Brink, Mirian, et al.
Publicado: (2022)

Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence
por: Misund, Kristine, et al.
Publicado: (2022)

First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018
por: Brink, Mirian, et al.
Publicado: (2021)

Improving Outcome-Driven Care in Multiple Myeloma Using Patient-Reported Outcomes: A Qualitative Evaluation Study
por: Bennink, Christine, et al.
Publicado: (2023)

2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde
por: Musto, Pellegrino, et al.
Publicado: (2021)

P899: HOVON 104; LONG TERM FOLLOW-UP OF AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER BORTEZOMIB INDUCTION THERAPY IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: Minnema, Monique, et al.
Publicado: (2023)

Functional and Structural Plasticity of Brain in Elite Karate Athletes
por: Duru, Adil Deniz, et al.
Publicado: (2018)

Differential quantities of immune checkpoint-expressing CD8 T cells in soft tissue sarcoma subtypes
por: Klaver, Yarne, et al.
Publicado: (2020)

Tumor-induced remote ECM network orientation steers angiogenesis
por: Balcioglu, Hayri E., et al.
Publicado: (2016)

Development of a Patient Centered Outcome Set for Patients With Multiple Myeloma to be Used in Clinical Practice
por: Oerlemans, Simone, et al.
Publicado: (2020)

Vistas in astronomy
por: Beer, Arthur
Publicado: (1968)

Vistas in astronomy
por: Beer, Arthur
Publicado: (1969)

Vistas in astronomy
por: Beer, Arthur
Publicado: (1960)

Vistas in nanofabrication
por: Rahman, Faiz
Publicado: (2013)

Vistas in astronomy
por: Beer, Arthur
Publicado: (1972)

Vistas of China
Publicado: (1987)

Vistas in astronomy
por: Beer, Arthur
Publicado: (1974)

Vistas in Nanofabrication
por: Rahman, Faiz
Publicado: (2012)

VISTA Trials
por: Gilotay, Caroline, et al.
Publicado: (2015)

Vistas for the future
por: Grewal, Anju
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_httljkqolc8rsg5bn9quilm3bp